Tempus AI, Inc(:TEM)
Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology c...
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|
net revenue | |||||||
genomics | 172,131,250 | 252,878,000 | 241,843,000 | 193,804,000 | 120,434,000 | 116,422,000 | 112,324,000 |
data and services | 54,013,250 | 81,328,000 | 72,792,000 | 61,933,000 | 80,246,000 | 64,507,000 | 53,645,000 |
total net revenue | 367,211,000 | 334,206,000 | 314,635,000 | 255,737,000 | 200,680,000 | 180,929,000 | 165,969,000 |
yoy | 82.98% | 84.72% | 89.57% | ||||
qoq | 9.88% | 6.22% | 23.03% | 27.44% | 10.92% | 9.01% | |
cost and operating expenses | |||||||
cost of revenues, genomics | 70,795,500 | 98,643,000 | 99,756,000 | 84,783,000 | 62,182,000 | 60,126,000 | 68,324,000 |
cost of revenues, data and services | 15,303,000 | 25,621,000 | 19,840,000 | 15,751,000 | 16,434,000 | 14,964,000 | 22,132,000 |
technology research and development | 40,147,000 | 38,087,000 | 34,482,000 | 33,391,000 | 31,864,000 | 30,680,000 | 77,908,000 |
research and development | 50,471,000 | 44,960,000 | 41,619,000 | 35,874,000 | 29,612,000 | 27,348,000 | 68,025,000 |
selling, general and administrative | 208,508,000 | 187,891,000 | 180,712,000 | 154,627,000 | 111,288,000 | 101,427,000 | 463,072,000 |
total cost and operating expenses | 428,624,000 | 395,202,000 | 376,409,000 | 324,426,000 | 251,380,000 | 234,545,000 | 699,461,000 |
income from operations | -61,413,000 | -60,996,000 | -61,774,000 | -68,689,000 | -50,700,000 | -53,616,000 | -533,492,000 |
yoy | 21.13% | 13.76% | -88.42% | ||||
qoq | 0.68% | -1.26% | -10.07% | 35.48% | -5.44% | -89.95% | |
operating margin % | -16.72% | -18.25% | -19.63% | -26.86% | -25.26% | -29.63% | -321.44% |
interest income | 5,122,000 | 4,600,000 | 1,093,000 | 1,813,000 | 3,546,000 | 4,789,000 | 1,718,000 |
interest expense | -15,286,000 | -15,399,000 | -21,579,000 | -18,003,000 | -13,359,000 | -13,761,000 | -13,295,000 |
loss on debt extinguishment | -12,034,000 | ||||||
other income | 14,568,000 | 2,605,000 | 41,729,000 | -27,455,000 | 50,157,000 | -11,522,000 | -7,048,000 |
loss before benefit from income taxes | -57,009,000 | -81,224,000 | -40,531,000 | -112,334,000 | |||
benefit from income taxes | 5,992,000 | -276,000 | -212,000 | 46,180,000 | |||
gains from equity method investments | -616,250 | 1,518,000 | |||||
net income | -54,166,000 | -79,982,000 | -42,843,000 | -68,037,000 | -13,014,000 | -75,840,000 | -552,212,000 |
yoy | 316.21% | 5.46% | -92.24% | ||||
qoq | -32.28% | 86.69% | -37.03% | 422.80% | -82.84% | -86.27% | |
net income margin % | -14.75% | -23.93% | -13.62% | -26.60% | -6.48% | -41.92% | -332.72% |
dividends on series a, b, b-1, b-2, c, d, e, f, g, g-3, and g-4 preferred shares | -11,540,000 | ||||||
cumulative undeclared dividends on series c preferred shares | -668,000 | ||||||
net loss attributable to common shareholders, basic and diluted | -54,166,000 | -79,982,000 | -42,843,000 | -68,037,000 | -13,014,000 | -75,840,000 | -564,420,000 |
net income per share | -0.31 | -0.46 | -0.25 | -0.4 | 0.81 | -0.46 | -6.86 |
weighted-average shares outstanding used to compute net loss per share, basic and diluted | 174,264 | 174,945 | 173,381 | 170,506 | 119,849 | 165,612 | 82,325 |
comprehensive loss, net of tax | |||||||
foreign currency translation adjustment | -4,631 | -2,915 | 3,756 | 4,598 | -10,114 | 10,302 | -43 |
comprehensive loss | -58,797 | -82,897 | -39,087 | -63,439 | -23,128 | -65,538 | -552,255 |
losses from equity method investments | -2,100,000 | -1,883,000 | -2,536,000 | -1,692,000 | |||
income before provision for income taxes | -10,356,000 | -74,110,000 | -552,117,000 | ||||
provision for income taxes | -122,000 | -38,000 | -95,000 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|
assets | |||||||
current assets | |||||||
cash and cash equivalents | 604,787,000 | 655,918,000 | 186,310,000 | 151,603,000 | 340,954,000 | 388,006,000 | 478,811,000 |
accounts receivable | 311,170,000 | 283,626,000 | 266,284,000 | 262,613,000 | 154,819,000 | 145,616,000 | 118,106,000 |
inventory | 51,724,000 | 54,976,000 | 47,600,000 | 50,485,000 | 38,386,000 | 36,138,000 | 32,690,000 |
related party asset | 8,785,000 | 5,660,000 | 2,535,000 | ||||
prepaid expenses and other current assets | 40,498,000 | 42,611,000 | 36,476,000 | 42,086,000 | 26,135,000 | 31,335,000 | 29,704,000 |
marketable equity securities | 150,211,000 | 103,720,000 | 104,996,000 | 67,183,000 | 107,309,000 | 78,317,000 | 11,255,000 |
total current assets | 1,167,175,000 | 1,146,511,000 | 644,201,000 | 573,970,000 | 667,603,000 | 679,412,000 | 671,366,000 |
property and equipment | 89,156,000 | 90,710,000 | 92,563,000 | 93,536,000 | 58,056,000 | 59,392,000 | 60,539,000 |
goodwill | 470,211,000 | 465,140,000 | 325,793,000 | 325,774,000 | 73,343,000 | 73,365,000 | 73,345,000 |
intangible assets | 355,253,000 | 372,876,000 | 387,564,000 | 399,544,000 | 11,716,000 | 14,289,000 | 16,252,000 |
investments and other assets | 21,111,000 | 20,948,000 | 16,669,000 | 14,811,000 | 8,305,000 | 8,692,000 | 7,677,000 |
investment in joint venture | 86,557,000 | 94,367,000 | 95,718,000 | 94,153,000 | 91,450,000 | 103,699,000 | |
related party asset, less current portion | 16,215,000 | 19,340,000 | 22,465,000 | ||||
operating lease right-of-use assets | 64,496,000 | 66,901,000 | 38,651,000 | 39,626,000 | 14,762,000 | 14,141,000 | 13,994,000 |
restricted cash | 4,664,000 | 4,631,000 | 1,741,000 | 1,723,000 | 881,000 | 872,000 | 861,000 |
total assets | 2,274,838,000 | 2,281,424,000 | 1,625,365,000 | 1,543,137,000 | 926,116,000 | 971,728,000 | 864,611,000 |
liabilities, convertible redeemable preferred stock, and stockholders' equity | |||||||
current liabilities | |||||||
accounts payable | 81,994,000 | 59,553,000 | 79,323,000 | 88,732,000 | 53,804,000 | 49,027,000 | 28,646,000 |
accrued expenses | 155,370,000 | 160,773,000 | 165,903,000 | 129,238,000 | 130,407,000 | 101,985,000 | 85,185,000 |
deferred revenue | 92,673,000 | 84,719,000 | 100,477,000 | 73,431,000 | 75,981,000 | 67,604,000 | 50,905,000 |
deferred other income | 15,955,000 | 15,955,000 | 15,955,000 | 15,955,000 | 15,955,000 | 15,955,000 | |
other current liabilities | 8,680,000 | 11,819,000 | 16,554,000 | 18,194,000 | 6,964,000 | 9,913,000 | 7,273,000 |
operating lease liabilities | 13,355,000 | 12,417,000 | 9,381,000 | 9,420,000 | 6,459,000 | 5,894,000 | 5,828,000 |
accrued data licensing fees | 4,361,000 | 4,792,000 | 5,567,000 | 1,500,000 | 1,500,000 | 2,242,000 | 3,727,000 |
total current liabilities | 372,388,000 | 350,028,000 | 418,160,000 | 336,470,000 | 291,070,000 | 252,620,000 | 181,564,000 |
operating lease liabilities, less current portion | 74,272,000 | 77,723,000 | 45,866,000 | 47,567,000 | 26,199,000 | 26,664,000 | 27,238,000 |
convertible promissory note | 208,672,000 | 217,959,000 | 226,342,000 | 233,620,000 | 168,192,000 | 174,460,000 | 180,648,000 |
other long-term liabilities | 56,600,000 | 58,772,000 | 9,508,000 | 9,670,000 | 15,980,000 | 15,403,000 | 16,790,000 |
revolving credit facility | 100,000,000 | 100,000,000 | 100,000,000 | 100,000,000 | |||
interest payable | 12,393,000 | 8,739,000 | 5,084,000 | 1,470,000 | 70,450,000 | 66,529,000 | 62,608,000 |
long-term debt | 202,753,000 | 200,859,000 | 471,663,000 | 467,144,000 | 267,244,000 | 264,527,000 | 261,853,000 |
convertible senior notes | 728,078,000 | 726,863,000 | |||||
deferred other income, less current portion | 7,977,000 | 11,966,000 | 15,955,000 | 19,944,000 | 23,932,000 | 27,921,000 | |
deferred revenue, less current portion | 20,379,000 | 20,691,000 | 23,225,000 | 1,058,000 | 6,710,000 | 12,976,000 | 2,059,000 |
total liabilities | 1,783,512,000 | 1,773,600,000 | 1,315,803,000 | 1,216,943,000 | 869,777,000 | 918,000,000 | 766,360,000 |
related party payable | 25,000,000 | ||||||
warrant asset | 800,000 | ||||||
deferred offering costs | |||||||
warrant asset, less current portion | 1,500,000 | ||||||
warrant contract asset, less current portion | 17,866,000 | 19,077,000 | |||||
accrued dividends | |||||||
warrant liability | 76,900,000 | 33,600,000 | |||||
commitments and contingencies | |||||||
convertible redeemable preferred stock, 0.0001 par value... | |||||||
liabilities, convertible redeemable preferred stock, and stockholders’ equity | |||||||
stockholders’ equity | |||||||
class a voting common stock, 0.0001 par value... | 15,000 | ||||||
class b voting common stock, 0.0001 par value... | 1,000 | ||||||
non-voting common stock, 0.0001 par value... | |||||||
treasury stock | -3,602,000 | ||||||
additional paid-in capital | 2,163,911,000 | ||||||
accumulated other comprehensive income | -94,000 | ||||||
accumulated deficit | -2,061,980,000 | ||||||
total stockholders’ equity | 98,251,000 | ||||||
total liabilities, convertible redeemable preferred stock, and stockholders’ equity | 864,611,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|
operating activities | ||||||
net loss | -54,166,000 | -79,982,000 | -42,843,000 | -68,037,000 | -13,014,000 | -75,840,000 |
adjustments to reconcile net loss to net cash from operating activities | ||||||
change in fair value of warrant liability | 0 | 43,300,000 | ||||
gain on warrant termination | ||||||
reversal of warrant contract asset amortization | ||||||
stock-based compensation | 45,339,000 | 33,979,000 | 22,455,000 | 22,974,000 | 24,787,000 | 21,038,000 |
gain on warrant exercise | 0 | 0 | ||||
gain on marketable equity securities | -11,740,000 | 1,276,000 | -6,991,000 | -2,578,000 | ||
loss on disposal of property and equipment | ||||||
loss on debt extinguishment | 0 | |||||
deferred income taxes | -6,449,000 | 0 | 0 | -46,216,000 | ||
losses from equity method investments | 3,149,000 | -1,518,000 | 2,100,000 | 1,883,000 | 2,536,000 | |
amortization of original issue discount | 1,473,000 | 1,446,000 | 609,000 | 560,000 | 346,000 | 345,000 |
amortization of deferred financing fees | 86,000 | 66,000 | 175,000 | 157,000 | 127,000 | 128,000 |
change in fair value of contingent consideration | -93,000 | 0 | ||||
change in fair value of holdback liability | -1,628,000 | -21,000 | 266,000 | 46,000 | ||
amortization of warrant contract asset | 1,210,000 | 1,211,000 | ||||
depreciation and amortization | 26,908,000 | 27,031,000 | 28,032,000 | 20,353,000 | 9,457,000 | 9,440,000 |
provision for bad debt expense | 1,791,000 | 142,000 | 309,000 | 316,000 | 135,000 | 218,000 |
provision for obsolete inventory | 200,000 | |||||
amortization of finance right-of-use lease assets | ||||||
change in fair value of warrant asset | 0 | -26,002,000 | ||||
non-cash operating lease costs | 3,688,000 | 3,293,000 | 2,484,000 | 2,089,000 | 1,377,000 | 1,418,000 |
minimum accretion expense | 159,000 | 1,000 | -140,000 | 248,000 | 112,000 | -7,000 |
impairment of intangible assets | ||||||
pik interest added to principal | 1,698,000 | 1,682,000 | 3,883,000 | 3,274,000 | 2,244,000 | 2,201,000 |
change in assets and liabilities | ||||||
accounts receivable | -27,203,000 | -14,044,000 | -3,980,000 | -45,175,000 | -9,338,000 | -27,728,000 |
inventory | 3,168,000 | -8,511,000 | 2,885,000 | -911,000 | -2,248,000 | -3,448,000 |
prepaid expenses and other current assets | 2,292,000 | -3,803,000 | 5,610,000 | -5,798,000 | 357,000 | -1,631,000 |
investments and other assets | -601,000 | -5,627,000 | -7,715,000 | -3,358,000 | -341,000 | -1,704,000 |
accounts payable | 11,287,000 | -25,553,000 | -16,547,000 | 23,572,000 | 924,000 | 8,595,000 |
related party asset | 0 | |||||
deferred revenue | -24,358,000 | -19,438,000 | 49,213,000 | -12,377,000 | -19,890,000 | 27,617,000 |
deferred other income | -3,989,000 | -3,989,000 | -3,989,000 | -3,988,000 | -3,989,000 | |
accrued data licensing fees | -764,000 | -227,000 | 4,207,000 | -250,000 | -750,000 | -1,501,000 |
accrued expenses & other | -7,665,000 | -12,170,000 | 34,597,000 | -27,606,000 | 27,169,000 | 26,176,000 |
interest payable | 3,918,000 | 3,166,000 | 3,614,000 | 3,508,000 | 3,921,000 | 3,921,000 |
operating lease liabilities | -3,796,000 | -5,210,000 | -3,249,000 | -2,693,000 | -1,898,000 | -2,073,000 |
net cash from operating activities | -36,788,000 | -119,842,000 | 44,164,000 | -105,624,000 | -39,251,000 | 48,664,000 |
capital expenditures | -4,755,000 | -6,706,000 | -7,654,000 | 4,929,000 | -10,376,000 | 5,555,000 |
free cash flows | -41,543,000 | -126,548,000 | 36,510,000 | -100,695,000 | -49,627,000 | 54,219,000 |
investing activities | ||||||
purchases of property and equipment | -4,755,000 | -6,706,000 | -7,514,000 | -2,074,000 | -7,962,000 | -43,000 |
proceeds from sale of marketable equity securities | 0 | 0 | 0 | 8,316,000 | 0 | 0 |
purchases of marketable equity securities | 0 | |||||
business combinations, net of cash acquired | -1,641,000 | 5,737,000 | 0 | -380,762,000 | ||
investment in joint venture | 0 | |||||
capitalized software costs | ||||||
net cash from investing activities | -10,717,000 | -2,309,000 | -9,511,000 | -375,818,000 | -7,962,000 | -131,412,000 |
financing activities | ||||||
proceeds from issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions | 0 | 0 | ||||
tax withholding related to net share settlement of restricted stock units | 0 | 0 | ||||
issuance of series g-4 preferred stock, net of offering costs | ||||||
issuance of series g-5 preferred stock | 0 | 0 | ||||
principal payments on finance lease liabilities | ||||||
purchase of treasury stock | ||||||
payment of deferred offering costs | -305,000 | -179,000 | -5,873,000 | |||
dividends paid | 0 | 0 | ||||
proceeds from revolving credit facility, net of original issue discount | 0 | 0 | 0 | 98,000,000 | ||
proceeds from long-term debt, net of original issue discount | 0 | 0 | 0 | 196,000,000 | ||
proceeds from convertible senior notes, net of initial purchasers' discount | 0 | |||||
payment of deferred financing fees | -264,000 | -297,000 | 0 | -958,000 | ||
payment of indemnity holdback related to acquisition | 0 | 0 | ||||
g-4 special payment | 0 | |||||
principal payments on long-term debt | 0 | |||||
prepayment premium on long-term debt | 0 | |||||
purchases of capped call | 0 | |||||
proceeds from issuance of common stock in connection with at-the-market offering, net of commissions | 0 | |||||
net cash from financing activities | -3,609,000 | 594,690,000 | 0 | 293,042,000 | -179,000 | -8,123,000 |
effect of foreign exchange rates on cash | 16,000 | -41,000 | 72,000 | -109,000 | 349,000 | 77,000 |
net increase in cash, cash equivalents and restricted cash | -51,098,000 | 472,498,000 | -47,043,000 | -90,794,000 | ||
cash, cash equivalents and restricted cash, beginning of period | 0 | 0 | 0 | 341,835,000 | 0 | 0 |
cash, cash equivalents and restricted cash, end of period | -51,098,000 | 472,498,000 | 34,725,000 | 153,326,000 | -47,043,000 | -90,794,000 |
cash, cash equivalents and restricted cash are comprised of: | ||||||
cash and cash equivalents | -51,131,000 | 469,608,000 | 34,707,000 | 151,603,000 | -47,052,000 | -90,805,000 |
restricted cash and cash equivalents | 33,000 | 2,890,000 | 18,000 | 1,723,000 | 11,000 | |
total cash, cash equivalents and restricted cash | -51,098,000 | 472,498,000 | 34,725,000 | 153,326,000 | -47,043,000 | -90,794,000 |
purchases of capitalized software | -1,340,000 | -1,997,000 | -1,298,000 | |||
supplemental disclosure of cash flow information | ||||||
cash paid during the year for interest | 13,369,000 | 13,131,000 | 10,849,000 | 7,146,000 | 6,978,000 | |
cash paid for income taxes | 437,000 | 79,000 | 38,000 | |||
supplemental disclosure of noncash investing and financing activities | ||||||
dividends payable | 0 | 0 | ||||
purchases of property and equipment, accrued but not paid | -140,000 | 7,003,000 | -2,414,000 | 5,598,000 | ||
redemption of convertible promissory note | 7,278,000 | 7,060,000 | 6,268,000 | 6,188,000 | ||
non-voting common stock issued in connection with business combinations | 0 | 0 | ||||
deferred financing fees, accrued but not yet paid | ||||||
deferred offering costs, accrued but not yet paid | -5,872,000 | |||||
operating lease liabilities arising from obtaining right-of-use assets | 1,447,000 | |||||
conversion of redeemable convertible preferred stock to common stock in connection with initial public offering | 0 | 0 | ||||
taxes related to net share settlement of restricted stock units not yet paid | -144,000 | 0 | ||||
reclassification of deferred offering costs to additional paid-in capital upon initial public offering | ||||||
class a voting common stock issued in connection with business combinations | 0 | 310,320,000 | ||||
issuance of series g-3 preferred stock | 0 | 0 | ||||
issuance of series g-4 preferred stock | 0 | 0 | ||||
convertible promissory note principal reset due to amendment | 0 | 72,488,000 | ||||
loss on marketable equity securities | 31,805,000 | |||||
net decrease in cash, cash equivalents and restricted cash | -188,509,000 | |||||
issuance of series g-3 preferred stock, net of offering costs | ||||||
restricted cash | ||||||
marketable equity securities received on accounts receivable | ||||||
non-voting common stock issued in connection with contingent consideration | ||||||
accretion of convertible preferred stock to redemption value | ||||||
finance lease liabilities arising from obtaining right-of-use-assets | ||||||
issuance of warrant | ||||||
issuance of common stock in connection with contingent consideration | ||||||
reclassificiation of deferred offering costs to additional paid-in capital upon initial public offering | 0 | |||||
loss from equity-method investments |